Abstract Library

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#4151 Identifying potential tumor drivers through integration of gene expression and DNA copy number in SI-NET

Introduction: The genetics of small intestine neuroendocrine tumors (SI-NETs) remains poorly understood. To date, only CDKN1B has been found recurrently mutated, in approximately 9% of cases. On the contrary, DNA copy number alterations are found in a majority of cases. The most frequent aberration is heterozygous loss of chromosome 18. In addition, loss of chromosome 11, and gains on chromosomes 4, 5 and 14 are common. The cellular mechanisms through which these alterations drive tumor development are unknown.

Conference:

Presenting Author: Backman S

Authors: Backman S, Barazeghi E, Norlén O, Hellman P, Stålberg P,

Keywords: SI-NET, RNA-Seq, Gene dosage, Haplo-insufficiency, Copy number,

#3309 Comprehensive genetic analysis of tumor suppressor genes Men1, PTEN, Rb1 and p53 in NETs in mice

Introduction: Tumor suppressor genes (TSGs) RB1, TP53 and PTEN are three of the most commonly mutated TSGs in human cancers. Multiple endocrine neoplasia type 1 (MEN1) gene is one of the most frequently mutated TSGs in human neuroendocrine tumors (NETs). Cooperative effects of genetic alterations of TSGs are frequently observed during carcinogenesis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Xu E, Vosburgh E, Wong C, Tang L, Levine A,

Keywords: neuroendocrine tumor, men1, rb, pten, p53,

#3120 Thinking and confusion about a well-differentiated grade 3 pancreatic neuroendocrine tumor

Introduction: In WHO Classification of Digestive System Tumors (2019 edition), pancreatic NENs are divided into well-differentiated NETs (including G1, G2, G3) and poorly differentiated NECs mainly based on the mitoses and Ki-67. G3 pNET and pNEC should have more than 20 mitoses/10 HPFs or their Ki-67 should be higher than 20%. However, WHO didn't clearly distinguish the Ki-67 cut-off value between them, and only 55% was recommended.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ma Y

Authors: Ma Y, Song L, Li X, Yang M, Wang F,

Keywords: pancreatic neuroendocrine carcinoma, pancreatic neuroendocrine tumor, G3, P53, ATRX, DAXX, MEN1,

#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors

Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, de Paula C, Donadio M, Barros M, Formiga M,

Keywords: hereditary syndrome, neuroendocrine tumors, germline variants,